Process Development Excellence to De-risk Manufacturing Challenges and Industrialize iPSC based Therapies

Time: 3:15 pm
day: Day One


  • Introduce some of the current challenges with development of commercially viable iPSC based therapies from a CDMO perspective.
  • Discuss best practices to de-risk the manufacturing and develop commercially viable iPSC derived cell therapies through implementation of innovative technologies with appropriate in process control and monitoring analytical methods.
  • Explore applying bioprocessing best practices to ensure controlled expansion and differentiation of pluripotent stem cells into specialized cells by eliminating open and variable manual unit operations while incorporating comprehensive characterization assays in the process to verify long term stability of the products.